<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mangoceuticals, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock</link>
<description>Latest news and press releases for Mangoceuticals, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mangoceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683598dc78dffbe2df1059bc.webp</url>
<title>Mangoceuticals, Inc. Common Stock</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock</link>
</image>
<item>
<title>Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-lawsuit-seeking-damages-exceeding-dollar73-million-against-former-technology-consulting-and-software-development-firm-clarity-ventures-inc</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-lawsuit-seeking-damages-exceeding-dollar73-million-against-former-technology-consulting-and-software-development-firm-clarity-ventures-inc</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on</description>
</item>
<item>
<title>Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-pct-patent-filing-for-mgx-0024-antiviral-technology-to-include-inhibiting-respiratory-or-orally-acquired-virus-infection-in-animals-or-birds-8</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-pct-patent-filing-for-mgx-0024-antiviral-technology-to-include-inhibiting-respiratory-or-orally-acquired-virus-infection-in-animals-or-birds-8</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of</description>
</item>
<item>
<title>Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-patented-mgx-0024-achieves-zero-respiratory-related-mortality-in-29000-bird-field-trials-and-demonstrates-prophylactic-benefit-against-h5n1-in-controlled-government-study</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-patented-mgx-0024-achieves-zero-respiratory-related-mortality-in-29000-bird-field-trials-and-demonstrates-prophylactic-benefit-against-h5n1-in-controlled-government-study</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the</description>
</item>
<item>
<title>MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangorx-experiences-initial-success-with-newly-launched-dollar99month-all-inclusive-injectable-testosterone-replacement-therapy-trt-treatment-program</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangorx-experiences-initial-success-with-newly-launched-dollar99month-all-inclusive-injectable-testosterone-replacement-therapy-trt-treatment-program</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacem</description>
</item>
<item>
<title>Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-closing-2-153800046</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-closing-2-153800046</guid>
<pubDate>Fri, 19 Dec 2025 15:38:00 GMT</pubDate>
<description>DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued shares of Common Stock and pre-funded warrants in a registered</description>
</item>
<item>
<title>Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-partnership-with-the-cube-group-to-launch-up-to-dollar100-million-solana-focused-digital-asset-treasury-dat-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-partnership-with-the-cube-group-to-launch-up-to-dollar100-million-solana-focused-digital-asset-treasury-dat-strategy</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:</description>
</item>
<item>
<title>Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-2-5-133000519</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-announces-2-5-133000519</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private pla</description>
</item>
<item>
<title>Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-provides-clarification-launch-branded-003700946</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-provides-clarification-launch-branded-003700946</guid>
<pubDate>Fri, 14 Nov 2025 00:37:00 GMT</pubDate>
<description>Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m</description>
</item>
<item>
<title>Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-partners-eli-lilly-novo-120000605</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-partners-eli-lilly-novo-120000605</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (t</description>
</item>
<item>
<title>Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-patented-mgx-0024-delivers-130000343</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-patented-mgx-0024-delivers-130000343</guid>
<pubDate>Tue, 27 May 2025 13:00:00 GMT</pubDate>
<description>Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as “MGX-0024”. The field studies were c</description>
</item>
<item>
<title>Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-strategic-entry-high-130000536</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-strategic-entry-high-130000536</guid>
<pubDate>Fri, 25 Apr 2025 13:00:00 GMT</pubDate>
<description>DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related asse</description>
</item>
<item>
<title>Mangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness Solutions</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-reengineering-self-care-blueprint-120000766</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-reengineering-self-care-blueprint-120000766</guid>
<pubDate>Thu, 24 Apr 2025 12:00:00 GMT</pubDate>
<description>MIAMI, FL / ACCESS Newswire / April 24, 2025 / For decades, the men's health space has remained largely stagnant-held back by legacy brands offering generic solutions and treatment protocols that too often felt like quick fixes rather than genuine ...</description>
</item>
<item>
<title>CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/ceo-spotlight-mangoceuticals-inc-reinventing-175500871</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/ceo-spotlight-mangoceuticals-inc-reinventing-175500871</guid>
<pubDate>Tue, 22 Apr 2025 17:55:00 GMT</pubDate>
<description>DALLAS, TX / ACCESS Newswire / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent ...</description>
</item>
<item>
<title>Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-expands-33-billion-addressable-130000419</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-expands-33-billion-addressable-130000419</guid>
<pubDate>Tue, 25 Mar 2025 13:00:00 GMT</pubDate>
<description>Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agre</description>
</item>
<item>
<title>Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-launch-peachesrx-womens-120000818</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-announces-launch-peachesrx-womens-120000818</guid>
<pubDate>Thu, 20 Feb 2025 12:00:00 GMT</pubDate>
<description>Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women’s health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women’s unique health needs. These new and innovative wo</description>
</item>
<item>
<title>Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-advances-antiviral-research-on-its-patented-respiratory-illness-prevention-technology-with-new-study-targeting-avian-flu-in-poultry-using-a-non-invasive-non-pharmaceutical-water-based-solution</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-advances-antiviral-research-on-its-patented-respiratory-illness-prevention-technology-with-new-study-targeting-avian-flu-in-poultry-using-a-non-invasive-non-pharmaceutical-water-based-solution</guid>
<pubDate>Wed, 12 Feb 2025 05:00:00 GMT</pubDate>
<description>Dallas, Texas, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing,</description>
</item>
<item>
<title>Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-advances-h1n1-efficacy-study-noting-significant-reduction-in-viral-load-in-phase-1-studies-and-engages-vipragen-biosciences-to-structure-h5n1-cohort-for-expanded-research</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-advances-h1n1-efficacy-study-noting-significant-reduction-in-viral-load-in-phase-1-studies-and-engages-vipragen-biosciences-to-structure-h5n1-cohort-for-expanded-research</guid>
<pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
<description>Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing,</description>
</item>
<item>
<title>Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-executes-exclusive-distribution-agreement-with-propre-energie-for-clinically-proven-dermytolr-skincare-treatment-targeting-hyperpigmentation</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-executes-exclusive-distribution-agreement-with-propre-energie-for-clinically-proven-dermytolr-skincare-treatment-targeting-hyperpigmentation</guid>
<pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
<description>Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a</description>
</item>
<item>
<title>Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-completes-acquisition-of-mushroom-based-wellness-and-innovations-patent</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-completes-acquisition-of-mushroom-based-wellness-and-innovations-patent</guid>
<pubDate>Thu, 19 Dec 2024 05:00:00 GMT</pubDate>
<description>Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing,</description>
</item>
<item>
<title>Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split</title>
<link>https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-initiates-investigation-into-potential-stock-manipulation-scheme-following-recent-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/mangoceuticals-inc-common-stock/news/mangoceuticals-inc-initiates-investigation-into-potential-stock-manipulation-scheme-following-recent-reverse-stock-split</guid>
<pubDate>Wed, 04 Dec 2024 05:00:00 GMT</pubDate>
<description>DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing,</description>
</item>
</channel>
</rss>